Study of a combination treatment for advanced ovarian cancer before surgery
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests two drugs (fluzoparib with famitinib or SHR-1701) given before surgery to shrink advanced ovarian, fallopian tube, or primary peritoneal cancer. The goal is to see if these treatments can make tumors small enough for complete removal or improve the surgery outcome.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been newly diagnosed with a high-grade (serious) type of ovarian, fallopian tube, or peritoneal cancer that has spread (stage 3 or 4).
- Your tumor cannot be fully removed by surgery at this time, or you are not healthy enough for immediate surgery.
- You have at least one tumor that can be measured on a CT or MRI scan.
- You have a genetic test showing you do not have a BRCA1 or BRCA2 gene mutation (wild type).
- Your blood counts and organ function are within certain limits (like adequate white blood cells, platelets, hemoglobin, and liver/kidney function).
- You are not pregnant and agree to use effective birth control during and for 6 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two oral drugs—fuzuloparib (a PARP inhibitor) and apatinib (which blocks blood vessel growth to tumors)—given before surgery for advanced ovarian cancer that cannot be removed right away. It is for people whose tumors have a specific genetic marker (HRD positive) and who have not had prior cancer treatment.
This trial tests whether combining fluzoparib (a PARP inhibitor) with or without bevacizumab (a blood vessel growth blocker) before surgery can shrink advanced ovarian cancer. It is for women with a BRCA gene mutation whose cancer cannot be fully removed with surgery right now.
This trial checks whether having surgery to remove as much tumor as possible, followed by ongoing targeted treatment, helps people with advanced ovarian (and related) cancers live longer and/or control cancer better. It specifically uses tumor-testing results to match patients and then continues treatment after surgery.
This trial tests a combination of two oral medications—fluzoparib (a PARP inhibitor) and famitinib (a TKI)—as maintenance therapy to keep advanced ovarian cancer from coming back after successful first-line chemotherapy. It is for women whose cancer responded well to initial platinum-based treatment.
This trial tests whether a combination of two drugs, fluzoparil and apatinib, can help keep ovarian cancer from coming back after platinum chemotherapy. It is for people whose cancer has either returned within 6 months (platinum-resistant) or after 6 months (platinum-sensitive) and who have responded to at least 4 more cycles of chemotherapy.
This is an observational (non-interventional) study that tracks how fluzoparib is used to treat ovarian, fallopian tube, or primary peritoneal cancer in real-world care. It may help doctors better understand how well the treatment works and what side effects patients experience.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.